Hot Life Science Investor Mandate 1: Global Pharmaceutical Company Seeking Therapeutic In-Licensing/Investment Opportunities

26 Jun

A global biopharmaceutical company with offices in the US and Europe is looking to in-license technology of interest and also makes select equity investments. The investment size is highly variable and has ranged from $1 million to $10s of millions. The firm invests in companies so the candidate technology can improve the lives of patients, not to make financial returns. The group does not have a goal for the number of deals this year. The firm made over 10 deals in the past year, and a few of these were equity investments. The group considers partnerships and investments globally.

The firm is interested in therapeutic biotechnology. The group is platform agnostic and will consider small molecules, biologics, or cell and gene therapy. Primary indications of interest include oncology, hematology, inflammation, and immunology. The firm will consider orphan indications but is less interested in ultra-orphan indications. The firm will consider companies across all phases of development, with a slight preference for later stage companies.

The firm prefers companies with experienced management teams and often seeks a board observer seat. Technologies of interest are generally not yet profitable. For equity deals, the firm does not want to be the first investor and prefers opportunities that have previous VC involvement. The group prefers to syndicate with other investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: